1830-42-8

Basic information

• Product Name: (2-AMino-5-chlorophenyl)(pyridin-2-yl)Methanone
• Synonyms: (2-AMino-5-chlorophenyl)(pyridin-2-yl)Methanone
• CAS NO: 1830-42-8
• Molecular Formula: C₁₂H₉ClN₂O
• Molecular Weight: 232.66566
• EINECS: -0
• Mol File: 1830-42-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 453.5°Cat760mmHg
• Flash Point: 228.1°C
• Appearance: /
• Density: 1.329g/cm³
• Vapor Pressure: 2.05E-08mmHg at 25°C
• Refractive Index: 1.642
• CAS DataBase Reference: (2-AMino-5-chlorophenyl)(pyridin-2-yl)Methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2-AMino-5-chlorophenyl)(pyridin-2-yl)Methanone(1830-42-8)
• EPA Substance Registry System: (2-AMino-5-chlorophenyl)(pyridin-2-yl)Methanone(1830-42-8)

Safety Data

• Hazardous Substances Data: 1830-42-8(Hazardous Substances Data)

Usage

General Description

The chemical (2-Amino-5-chlorophenyl)(pyridin-2-yl)Methanone, also known as ACPM, is a compound with the molecular formula C12H9ClN2O. It is a yellow solid that is commonly used in the synthesis of pharmaceuticals and agrochemicals. ACPM is a heterocyclic aromatic compound that contains both an amino group and a carbonyl group, making it versatile for use in various chemical reactions. Its unique structure and reactivity make it a valuable building block for the production of a wide range of organic compounds. Additionally, it has been studied for its potential biological activities, including as an anti-cancer agent and a dopamine receptor modulator.

InChI:InChI=1/C12H9ClN2O/c13-8-4-5-10(14)9(7-8)12(16)11-3-1-2-6-15-11/h1-7H,14H2

Upstream product

• 109-04-6 2-bromo-pyridine 
• 150879-48-4 N-methyl-N-methyloxy-2-amino-5-chlorobenzamide 
• 635-21-2 5-chloroanthranilic acid 
• 341521-27-5 (2-benzoylphenyl)carbamic acid tert-butyl ester 
• 525590-09-4 [4-chloro-2-(hydroxy-pyridin-2-yl-methyl)-phenyl]-carbamic acid tert-butyl ester 
• 18437-66-6 N-(t-butoxycarbonyl)-4-chloroaniline 
• 1121-60-4 pyridine-2-carbaldehyde 
• 308243-41-6 [4-chloro-2-(pyridine-2-carbonyl)-phenyl]-carbamic acid tert-butyl ester 
• 17624-36-1 2-pyridyllithium 

Downstream Products

• 308243-49-4 3-[7-chloro-2-(2-hydroxy-1-methyl-ethylamino)-5-pyridin-2-yl-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 
• 308243-52-9 3-[7-chloro-2-(2-hydroxy-1-methyl-propylamino)-5-pyridin-2-yl-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 
• 308242-66-2 methyl (S)-3-(8-chloro-1,2-dimethyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl) propanoate 
• 308243-48-3 3-[7-chloro-2-(2-hydroxy-propylamino)-5-pyridin-2-yl-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 
• 308243-53-0 3-[7-chloro-2-(2-hydroxy-ethylamino)-5-pyridin-2-yl-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 
• 308242-61-7 methyl (S)-3-(8-chloro-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate 
• 308242-63-9 methyl (S)-3-(8-chloro-2-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl) propanoate 

Relevant articles and documents

SHORT-ACTING BENZODIAZEPINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF

The present invention relates to a benzodiazepine derivative of Formula I as a short-acting anesthetic, a pharmaceutical composition comprising the same, a kit comprising the same, a preparation method thereof, an method of anesthesia using the same and use thereof in the manufacture of an anesthetic medicament.

QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formulae I and II: (I) (II) wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Relating the structure, activity, and physical properties of ultrashort-acting benzodiazepine receptor agonists

The ultrashort-acting benzodiazepine (USA BZD) agonists reported previously have been structurally modified to improve aqueous solubility. Lactam-to-amidine modifications, replacement of the C5-haloaryl ring, and annulation of heterocycles are presented. These analogues retain BZD receptor potency and full agonism profiles.